Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 12:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non-coumadin Oral Anticoagulant Clear all

Conditions: Atrial Fibrillation, Stroke, Bleeding
Interventions: Rivaroxaban, Warfarin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atrial Fibrillation
Interventions: Apixaban, Parenteral heparin and/or oral Vitamin K antagonist; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 63
States / cities: Birmingham, Alabama • Avondale, Arizona • Chula Vista, California + 32 more

Conditions: Non-Valvular Atrial Fibrillation
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 466,991 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Post-Operative Atrial Fibrillation
Interventions: AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems, Anticoagulation Therapy; Device · Drug
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 562 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 22
States / cities: San Diego, California • Stanford, California • Orlando, Florida + 15 more

Conditions: Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions: Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 811 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 151
States / cities: Chula Vista, California • Fremont, California • Fresno, California + 104 more

Conditions: Atrial Fibrillation (AF)
Interventions: Not listed
Lead sponsor: McMaster University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1,780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 4
States / cities: Evanston, Illinois • Detroit, Michigan • Great Neck, New York + 1 more

Conditions: Atrial Fibrillation
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 66
States / cities: Mobile, Alabama • Scottsdale, Arizona • East Palo Alto, California + 58 more

Conditions: Atrial Fibrillation, Stroke, Embolism
Interventions: Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 14,269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 295
States / cities: Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more

Conditions: Atrial Fibrillation, Frailty, Anticoagulant-induced Bleeding, Stroke
Interventions: Warfarin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years and older
Enrollment: 1,000,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stroke
Interventions: Monitored (M+); Device
Lead sponsor: AiCure; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Uterine Hemorrhage
Interventions: Direct oral anticoagulant (DOACs), Warfarin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 961,985 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
Interventions: Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care; Other · Diagnostic Test
Lead sponsor: Region Skane; Other
Eligibility: 18 Years and older
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation, Stroke, Systemic Embolism, Deep Venous Thrombosis
Interventions: Apixaban, Warfarin; Drug
Lead sponsor: Sanford Health; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Atrial Fibrillation, Obesity, Anticoagulants
Interventions: Apixaban; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 107,383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Atrial Fibrillation (AF)
Interventions: discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation; Behavioral · Drug · Procedure
Lead sponsor: China National Center for Cardiovascular Diseases; Government
Eligibility: 18 Years and older
Enrollment: 3,160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atrial Fibrillation, Ischemic Stroke, Acute
Interventions: Left Atrial Appendage Occlusion; Other
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Multiple Myeloma, Plasma Cell Neoplasm
Interventions: Lenalidomide, Dexamethasone, Anticoagulants; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 16
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more

Conditions: Atrial Fibrillation
Interventions: Non-coumadin Oral Anticoagulant; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Chicago, Illinois • Boston, Massachusetts

Search by objective public record fields.

Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation

AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty

Using Artificial Intelligence to Measure and Optimize Adherence in Patients on Anticoagulation Therapy.

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

International Care Bundle Evaluation in Cerebral Hemorrhage Research

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare

Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation

Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring